Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

DMAC

Live52w high -45.5%

Annual Quarterly

Core line items from DMAC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Entity: DIAMEDICA THERAPEUTICS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2018 2018-12-31	Q3 2018 2018-09-30
Revenue	$0.00	$500.00K	$500.00K
Operating Income	Not available	$-6.76M	$-4.64M
Net Income	Not available	$-5.73M	$-3.77M
EPS (Diluted)	$-0.20	Not available	Not available
Total Assets	Not available	$18.34M	Not available
Total Liabilities	Not available	Not available	Not available
Cash & Equivalents	Not available	$16.82M	$3.90M
Free Cash Flow OCF − CapEx	Not available	$-5.75M	$-3.86M
Shares Outstanding	Not available	11.96M	Not available

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from DMAC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -45.5%

Entity: DIAMEDICA THERAPEUTICS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-10	Annual 2018 2018-12-31	Q3 2018 2018-09-30
Revenue	$0.00	$500.00K	$500.00K
Operating Income	Not available	$-6.76M	$-4.64M
Net Income	Not available	$-5.73M	$-3.77M
EPS (Diluted)	$-0.20	Not available	Not available
Total Assets	Not available	$18.34M	Not available
Total Liabilities	Not available	Not available	Not available
Cash & Equivalents	Not available	$16.82M	$3.90M
Free Cash Flow OCF − CapEx	Not available	$-5.75M	$-3.86M
Shares Outstanding	Not available	11.96M	Not available

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.